Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2016

View Archived Issues

Researchers present promising data for the novel Mdm2 inhibitor NVP-HDM201

Arbaclofen ER compared to baclofen in multiple sclerosis patients with spasticity

GlaxoSmithKline and Anacor Pharmaceuticals exploit novel mechanism for treating tuberculosis

SAR-428926, a novel ADC with promising activity in preclinical models of cancer

Pneumococcal infection model reveals protective effects of B-cell epitopes

Bayer Schering Pharma patents CDK inhibitors

Merck & Co. discloses ROMK blockers

Positive results reported from two phase III studies of SUN-101/eFlow for COPD

X-Chem achieves milestone in Alexion collaboration

Janssen Pharmaceutica describes FFAR1 agonists

Adimab enters two new antibody collaborations

Protagonist Therapeutics presents LPAM-1 receptor antagonists

Positive results from phase II study of AZP-531 in Prader-Willi Syndrome

First patient randomized in the dalGenE phase III cardiovascular outcomes trial

Cosmo Technologies reports AR and GR antagonists

Cumberland Pharmaceuticals commences new systemic sclerosis program for ifetroban

Sanofi enters collaborations to predict diabetes medication adherence

Grant supports University of Manchester's research in frontotemporal lobar degeneration

FDA extends PDUFA date for Heplisav-B BLA

Biosortia announces new oncology research projects

Sanofi makes proposal to acquire Medivation

Clinical trial investigates gene therapy for Batten disease CLN6

First patient dosed in phase I trial of Agenus' AGEN-1884

Shionogi reports promising phase II data for Japanese Cedar pollen sublingual immunotherapy tablet

E.U. approval for TachoSil for use in neurological surgery

Lonsurf approved in Europe

FDA accepts OPKO's resubmitted NDA for calcifediol

AbGenomics reports final results from phase II trial of neihulizumab in psoriatic arthritis